Physiological and Pharmacological Modulation of the Embryonic Skeletal Muscle Calcium Channel Splice Variant CaV1.1e  by Benedetti, Bruno et al.
1072 Biophysical Journal Volume 108 March 2015 1072–1080ArticlePhysiological and Pharmacological Modulation of the Embryonic Skeletal
Muscle Calcium Channel Splice Variant CaV1.1eBruno Benedetti,1 Petronel Tuluc,1,2 Vincenzo Mastrolia,1 Clemens Dlaska,1 and Bernhard E. Flucher1,*
1Department of Physiology and Medical Physics, Medical University Innsbruck, Innsbruck, Austria; and 2Pharmacology and Toxicology,
Institute of Pharmacy, University of Innsbruck, Innsbruck, AustriaABSTRACT CaV1.1e is the voltage-gated calcium channel splice variant of embryonic skeletal muscle. It differs from the adult
CaV1.1a splice variant by the exclusion of exon 29 coding for 19 amino acids in the extracellular loop connecting transmembrane
domains IVS3 and IVS4. Like the adult splice variant CaV1.1a, the embryonic CaV1.1e variant functions as voltage sensor in
excitation-contraction coupling, but unlike CaV1.1a it also conducts sizable calcium currents. Consequently, physiological or
pharmacological modulation of calcium currents may have a greater impact in CaV1.1e expressing muscle cells. Here, we
analyzed the effects of L-type current modulators on whole-cell current properties in dysgenic (CaV1.1-null) myotubes reconsti-
tuted with either CaV1.1a or CaV1.1e. Furthermore, we examined the physiological current modulation by interactions with the
ryanodine receptor using a chimeric CaV1.1e construct in which the cytoplasmic II-III loop, essential for skeletal muscle excita-
tion-contraction coupling, has been replaced with the corresponding but nonfunctional loop from the Musca channel. Whereas
the equivalent substitution in CaV1.1a had abolished the calcium currents, substitution of the II-III loop in CaV1.1e did not
significantly reduce current amplitudes. This indicates that CaV1.1e is not subject to retrograde coupling with the ryanodine re-
ceptor and that the retrograde coupling mechanism in CaV1.1a operates by counteracting the limiting effects of exon 29 inclusion
on the current amplitude. Pharmacologically, CaV1.1e behaves like other L-type calcium channels. Its currents are substantially
increased by the calcium channel agonist Bay K 8644 and inhibited by the calcium channel blocker nifedipine in a dose-depen-
dent manner. With an IC50 of 0.37 mM for current inhibition by nifedipine, CaV1.1e is a potential drug target for the treatment
of myotonic dystrophy. It might block the excessive calcium influx resulting from the aberrant expression of the embryonic splice
variant CaV1.1e in the skeletal muscles of myotonic dystrophy patients.INTRODUCTIONThe voltage-gated calcium channel isoform CaV1.1 func-
tions as the voltage sensor in skeletal muscle excitation-
contraction (EC) coupling. This primary function of
CaV1.1 depends on its physical interaction with the skeletal
muscle ryanodine receptor (RyR1), but does not require
calcium influx through the voltage-gated calcium channel
itself. In fact, the classical adult CaV1.1a splice variant
requires ~30 mV stronger depolarization to activate its
L-type calcium current (LTCC) than to activate EC coupling
(1). Moreover, CaV1.1a currents are small and slowly acti-
vating. Of importance, expression of these currents depends
on the interaction of CaV1.1a with the RyR1. In the absence
of RyR1—either in dyspedic (RyR1-null) myotubes or
when CaV1.1a is expressed in heterologous cells—LTCC
are barely detectable (2,3). Thus, in skeletal muscle
CaV1.1 and RyR1 functionally interact with each other in
two directions: By orthograde coupling the CaV1.1 voltage
sensor prompts the gating of the RyR1 calcium releaseSubmitted August 13, 2014, and accepted for publication January 28, 2015.
*Correspondence: bernhard.e.flucher@i-med.ac.at
This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Bruno Benedetti and Petronel Tuluc contributed equally to this work.
Editor: Randall Rasmusson.
 2015 The Authors
0006-3495/15/03/1072/9 $2.00channel in response to membrane depolarization. By retro-
grade coupling the RyR1 augments the LTCC through
CaV1.1a severalfold.
Recently, we identified a splice variant of CaV1.1
(CaV1.1e), which is the dominant CaV1.1 expressed in em-
bryonic skeletal muscle (4). It is generated by skipping exon
29 and results in a channel lacking 19 amino acids in the
extracellular loop connecting transmembrane segments S3
and S4 in the fourth homologous repeat. Like the full-length
CaV1.1a, CaV1.1e is incorporated into skeletal muscle triads
and can activate EC coupling independent of calcium con-
duction through the channel (5). However, in contrast to
the poor gating properties of the adult CaV1.1a channel,
the embryonic CaV1.1e splice variant conducts calcium
currents that are 6–8 times larger than those of CaV1.1a,
and activation of its current and of EC coupling occur at
the same membrane potentials. Thus, the embryonic
CaV1.1e splice variant combines skeletal muscle-type EC
coupling properties with cardiac muscle-like calcium cur-
rents. However, currently it is not known whether CaV1.1e
also supports retrograde coupling.
Both, orthograde and retrograde coupling critically
depend on a specific sequence in the cytoplasmic loop con-
necting homologous repeats II and III of skeletal muscle
CaV1.1 channels. When the critical II-III loop sequenceshttp://dx.doi.org/10.1016/j.bpj.2015.01.026
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CaV1.2 isoform (6) or more distantly related CaV1 channels,
skeletal muscles EC coupling, as well as retrograde
coupling failed (7,8). Because CaV1.1e contains the critical
II-III loop sequences and displays normal orthograde
coupling, it is expected to also show retrograde coupling.
Continued expression of the embryonic CaV1.1e splice
variant in mature muscles was shown to correlate with the
degree of muscle weakness in patients with myotonic dys-
trophy (9). Furthermore, forced skipping of exon 29 aggra-
vated the disease phenotype in a mouse model of myotonic
dystrophy, suggesting that expression of the calcium-con-
ducting CaV1.1e variant in adult muscle may contribute to
the etiology of myotonic dystrophy phenotype (9,10).
Therefore, use of clinically approved calcium antagonists
may be of therapeutic use in the treatment of myotonic
dystrophy, provided the CaV1.1e splice variant is sensitive
to L-type channel blockers.
The family of CaV1 channels is sensitive to dihydropyri-
dines (DHPs). Bay K 8644 augments LTCC by shifting the
fraction of total channel open events markedly to the long
opening mode without altering the rate of activation (11).
Channel blockers, like nifedipine, reduce the current density
by stabilizing the inactivated state of the channel (12).
Because skipping of exon 29 does not affect the sequences
known to bind DHPs, CaV1.1e would be expected to show
DHP sensitivity. On the other hand, because Bay K 8644
as well as deletion of exon 29 enhance the current density
with little effect on the rate of activation, it is possible
that Bay K 8644 acts on the same downstream molecular
mechanism that is altered in CaV1.1e. In this case a reduced
sensitivity of CaV1.1e to Bay K 8644 would be expected.
Here, we reconstituted dysgenic myotubes with either
the CaV1.1e or the CaV1.1a splice variant to characterize their
sensitivity to DHPs, or with a CaV1.1e chimera in which
the II-III loop has been replaced with the corresponding
sequences of the Musca CaV1 channel to examine its interac-
tions with RyR1. Our pharmacological analysis shows that
CaV1.1e LTCC can be blocked by nifedipine or further
increased by Bay K 8644. However, replacing the II-III
loop abolished skeletal muscle-type EC coupling without
reducing the LTCC amplitude, indicating that wild-type
CaV1.1e currents are not augmented by retrograde coupling
with the RyR1. These findings suggest that the inclusion of
exon 29 in the adult CaV1.1a splice variant applies a brake
on voltage-dependent current activation that is partially alle-
viated by retrograde coupling with the RyR1. In the absence
of this brake in CaV1.1e retrograde coupling is ineffective.MATERIALS AND METHODS
Expression plasmids
CaV1.1a: GFP-a1S (13); CaV1.1e: GFP-a1S-DE29 (5). CaV1.1e-SkLM:
GFP-SkLM-DE29 was generated by excising a 1777 bp fragmentcontaining the second half of repeat III and repeat IV using BglII and
XhoI enzymes from GFP-a1S-DE29 plasmid (5) and ligating it into
the homologous region of the GFP-a1S-SKLM channel previously
described (7).Muscle cell culture and transfection
Myotubes of the homozygous dysgenic (mdg/mdg) cell line GLT were
cultured as previously described (14). At the onset of myoblast fusion,
GLT cell cultures were transfected with plasmids coding for the calcium
channel subunits using FuGeneHD transfection reagent (Promega,
Mannheim, Germany) according to the manufacturer’s instructions. A total
of 1 mg of plasmid DNA was used per 30 mm culture dish.Electrophysiology, fluorescence calcium
recording, and pharmacology
Patch pipettes (borosilicate glass, Harvard Apparatus, Holliston, MA) had
resistance of 1.5–3 MU when filled with (mM) 145 Cs-aspartate, 2
MgCl2, 10 HEPES, 0.1 Cs-EGTA, 2 Mg-ATP, and 0.2 Fluo-4 when calcium
transients were recorded in parallel to calcium influx (pH 7.4 with CsOH).
The extracellular bath solution contained (mM) 10 CaCl2, 145 tetraethy-
lammonium chloride, 10 HEPES (pH 7.4 with tetraethylammonium
hydroxide). To block the inward calcium currents, 0.5 mM Cd2þ and
0.2 mM La3þ (Cd2þ/ La3þ) were added to the bath solution. All recordings
were made with an Axopatch 200A amplifier (Axon Instruments, Foster
City, CA). Data acquisition and command potentials were controlled
by pClamp software (version 8.0, Axon Instruments). Fluorescent calcium
signals were recorded in parallel to patch clamp recordings using PTI
photomultipliers (Photon Technology International, Seefield, Germany).
The voltage dependence of currents and calcium signals were analyzed
as described in (4). DHPs were dissolved in dimethyl sulfoxide (DMSO)
at the concentration of 1 mM and diluted in the bath solution at the
following concentrations (mM): Bay K 8644: 1, Nifedipine: 0.1, 0.5, 5.
When the highest concentration of DMSO (0.5%) was also applied to the
bath solution in absence of DHPs, it had scarce effect on the calcium
currents (IMax DMSO/IMax control ¼ 0.8 5 0.09) and voltage dependence
(55 1 mV) of CaV1.1e.DHP application
The effect ofDHPswere tested involtage-clampexperimentswith amultiple-
sweep protocol containing 200 ms long pulses from 50 mV to þ80 mV
in 10 mV increments before and after DHPs application. Between sweeps,
the membrane voltage was kept at 80 mV (Ihold < 100 pA). To inactivate
T-type currents, a 50 ms prepulse (to 50 mV) was applied before each
sweep. Series resistance (Rs) was monitored between protocols, rejecting
recordings with Rs drift > 20% or with Rs > 12 mU. After stable control
recordings, the DHP-containing extracellular solution was applied at a flow
rate of 1.5–2.5 ml/min, replacing at least twice the chamber volume. In these
conditions, after 6 to 8min of drug application, full drug effect was observed.
Tail current amplitude was measured before and after Bay K 8644 appli-
cation to quantify the changes in open probability (Po), assuming that no sig-
nificant changes in the number of channels in the cell membrane occurred
within 6–8 min of drug application. We have never observed a rundown of
CaV1.1a or CaV1.1e in dysgenic myotubes.Immunofluorescence and antibodies
Immunofluorescence analysis was performed as described (15) using
the following antibodies: rabbit polyclonal anti-GFP (1:4,000; Molecular
Probes, Eugene, OR); mouse monoclonal anti-RyR (34-C; 1:1000;
Alexis Biochemicals, Lausen, Switzerland); secondary goat-antimouseBiophysical Journal 108(5) 1072–1080
1074 Benedetti et al.Alexa-594 and goat-antirabbit Alexa-488 (1:4,000; Molecular Probes).
Images were captured on a Zeiss Axiophot microscope with a cooled
charge-coupled device camera and METAVUE image-processing software
(Universal Imaging, West Chester, PA).RESULTS
CaV1.1e currents can be augmented by the L-type
calcium channel agonist Bay K 8644
Dysgenic myotubes lack the skeletal muscle calcium chan-
nel CaV1.1 and consequently also fail to exhibit LTCC and
EC coupling. Both functions can readily be reconstituted by
transfection of dysgenic myotubes with CaV1.1 expression
plasmids. First, we transfected dysgenic myotubes cultured
from the GLT cell line (14) with plasmids encoding either
the adult CaV1.1a (GFP-a1S) or the embryonic CaV1.1e
(GFP-a1S-DE29) splice variants. Whole-cell voltage-clamp
analysis of myotubes expressing one or the other splice
variant revealed calcium currents with greatly distinct prop-
erties (Fig. 1). As previously shown (4) CaV1.1a currents
were small (2.05 0.2 pA/pF) and reached half-maximal
activation at þ35.1 5 1.7 mV (Table 1; V1/2), whereas
CaV1.1e currents had five times larger current amplitudes
(10.4 5 0.5 pA/pF) and a half-maximal activation
at þ6.4 5 1.8 mV. During the 200 ms test pulse both
currents showed little inactivation. Previously, we demon-FIGURE 1 Bay K 8644 sensitivity of the embryonic CaV1.1e and adult CaV1.
patch clamp recordings before and after Bay K 8644 (gray) application from dy
Currents (IMax) elicited by depolarizing pulses to peak current potential (VMax), c
plots indicate that 10 mMBay K 8644 augments the current densities and left-shi
(red). (D) Box plots (left) of the ratio between peak currents before and after ap
ratio between tail currents recorded at 80 mV following a þ60 mV test pulse.
Representative tail currents (right) of Cav1.1a (blue) and Cav1.1e (red) befor
of CaV1.1a (blue) or CaV1.1e (red) stimulated by three different Bay K 8644 c
dependent in the small currents of Cav1.1a compared to the large Cav1.1e curr
Biophysical Journal 108(5) 1072–1080strated that the different calcium current amplitudes are
due to different biophysical properties of the two CaV1.1
splice variants and not to different expression levels (4).
Because the observed effects of deleting exon 29—
increased current amplitude, left-shifted voltage-dependence
of activation, but little change in the rate of activation—
closely resemble the known effects of the current-enhancing
gating modifier Bay K 8644 (11), we wondered whether
skipping of exon 29 in CaV1.1e and the drug action
might converge on a common downstream gating mecha-
nism, and thus render CaV1.1e insensitive to Bay K 8644.
To examine the possible additivity of Bay K 8644 effects,
we recorded whole-cell calcium currents of myotubes
expressing CaV1.1a or CaV1.1e before and after bath
application of Bay K 8644. Fig. 1 A shows the expected
effects of Bay K 8644 on current properties of myotubes
expressing CaV1.1a. After application of the highest dose
of Bay K 8644 (10 mM), the peak current amplitude of
Cav1.1a was increased more than fourfold (9.2 5
0.8 pA/pF). The half-maximal activation was left-shifted
by 19.1 5 1.5 mV (Table 1). Augmentation of the current
density was also observed in myotubes transfected with
CaV1.1e (Fig. 1, A–C). After Bay K 8644 application, the
average peak current amplitude was increased by approxi-
mately twofold (19.6 5 1.5 pA/pF). The half-maximal
activation was left-shifted by 9.35 2.6 mV. The fractional1a calcium channel splice variants in skeletal myotubes. (A) Representative
sgenic myotubes reconstituted with either CaV1.1a (blue) or CaV1.1e (red).
harge carrier 10 mM calcium. (B and C) I/V curves and fractional activation
fts the voltage-dependence of activation in both CaV1.1a (blue) and CaV1.1e
plication of 10 mM Bay K 8644 recorded at þ40 mV test pulses, and of the
Both ratios are significantly larger in Cav1.1a than in Cav1.1e (p ¼ 0.002).
e and after Bay K 8644 application (gray). (E) Relative increase in IMax
oncentrations. The effect of Bay K 8644 is much larger and concentration
ents. To see this figure in color, go online.
TABLE 1 Properties of adult and embryonic CaV1.1 currents
CaV1.1a CaV1.1e
Control (n ¼ 15)
Bay K 0.1 mM
(n ¼ 3)
Bay K 1 mM
(n ¼ 8)
Bay K 10 mM
(n ¼ 7) Control (n ¼ 15)
Bay K 0.1 mM
(n ¼ 4)
Bay K 1 mM
(n ¼ 8)
Bay K 10 mM
(n ¼ 7)
Ipeak 2.05 0.2 pA/pF 1.8 5 0.1 3.7 5 0.4 4.45 0.6 10.45 0.5 pA/pF 1.55 0.2 2.0 5 0.1 2.0 5 0.2
V1/2 (mV) 35.15 1.7 15.05 6.2 7.4 5 1.2 19.15 1.5 6.45 1.8 10.85 5.4 12.55 1.8 9.3 5 2.6
All data are presented as mean5 SE of the mean. Ipeak values with BayK are presented as fold increase compared to the control.V1/2 values with BayK are
expressed as voltage shifts from the control.
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potential eliciting the maximal current amplitude was the
same before and after the application of Bay K 8644 for
both CaV1.1a (20.1 5 0.03%) and CaV1.1e (22 5 0.1%).
Thus, CaV1.1e is sensitive to Bay K 8644 and the effect of
exon 29 skipping and that of the channel agonist are partially
additive. However, the effects of Bay K 8644 on Cav1.1a and
Cav1.1e are quantitatively different. Bay K 8644 increased
the maximal current (IMax) of Cav1.1a in a dose-dependent
manner (Fig. 1, D and E), at concentrations between
0.1 mM (approximately twofold) and 10 mM (~4.5-fold).
This did not occur for Cav1.1e, where the increase of IMax
saturated (approximately twofold) at Bay K 8644 concentra-
tions of 1 mM. The apparently weaker effects of Bay K 8644
on current amplitudes could be partially explained by the
much larger leftward shift in the voltage dependence of
activation induced by Bay K 8644 on CaV1.1a currents
compared to CaV1.1e currents. To quantify the agonistic ef-
fect of Bay K 8644 at the same driving force we also exam-
ined the relative increase of tail currents in response to Bay
K 8644 for both channel variants (Fig. 1 D). The ratio of tail
current amplitudes before and after application of Bay K
8644 is significantly larger (p ¼ 0.0006) for Cav1.1a (7.1
5 0.9) compared to Cav1.1e (2.75 0.2). Together, these re-FIGURE 2 Nifedipine block of CaV1.1e calcium currents. (A) Representative
of the LTCC-blocker nifedipine in dysgenic myotubes transfected with GFP-a1S
density at all voltages in a dose-dependent manner. (C) Nifedipine (0.5 mM) d
response curve of nifedipine-block indicates a IC50 of 0.37 mM. To see this figsults show that indeed the effects of Bay K 8644 on voltage
sensitivity and current amplitude in CaV1.1e are less than
half the magnitude of those in CaV1.1a.CaV1.1e currents are sensitive to the L-type
calcium channel blocker nifedipine
Given our finding that CaV1.1e is sensitive to the agonistic
DHP Bay K 8644, it was reasonable to assume that it also
would be blocked by antagonistic DHPs. We tested this
notion by patch clamp recording of dysgenic myotubes
expressing CaV1.1e before and after incubation with 0.1,
0.5, and 5.0 mM of nifedipine for 10 min. The sample
current traces in Fig. 2 A show that nifedipine at all three
concentrations reduced the current amplitude. The highest
used concentration of 5 mM nifedipine reduced the peak
current density to below 10% (1.4 5 0.3 pA/pF; Table 2)
of that in untreated controls (14.7 5 2.0 pA/pF) and to
14% compared to controls with the corresponding concen-
tration of the vehicle (0.5% DMSO) (9.7 5 1.0 pA/pF).
The IC50 for the nifedipine block of CaV1.1e currents
calculated from the dose-response curve is at 0.37 mM
(see Fig. 2D), which is in the same range that has previously
been reported for Cav1.2 (16,17) and Cav1.1a (18) incalcium current recordings before and after application of 0.1, 0.5, or 5 mM
-DE29 (CaV1.1e). (B) I/V curves show that nifedipine decreases the current
id not affect the voltage-dependence of current activation. (D) The dose-
ure in color, go online.
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TABLE 2 Nifedipine effect on embryonic CaV1.1e currents
Nifedipine – 0,1 mM 0,5 mM 5 mM
Ipeak (pA/pF) 14.75 2.0 11.95 2.0 6.55 2.0 1.45 0.3
V1/2 (mV) 2.75 1.2 – 4.35 2.2 –
n 12 3 5 4
All data are presented as mean5 SE of the mean.
1076 Benedetti et al.similar cell systems. The IV curves of currents at all three
nifedipine concentrations show that the voltage-dependence
of activation is scarcely affected by the nifedipine block
(Fig. 2 B). The 5 mV shift of fractional activation at
0.5 mM nifedipine (Fig. 2 C) is likely due to the strong
reduction in current amplitude. Thus, the DHP nifedipine
inhibits CaV1.1e calcium currents in skeletal myotubes in
a concentration-dependent manner, like any other LTCC.
Because LTCC through the adult CaV1.1a splice variant
are already exceedingly small and functionally irrelevant
in physiological EC coupling, we did not attempt to quantify
the further reduction of CaV1.1a currents by nifedipine.Replacement of II-III loop sequences in CaV1.1e
abolishes skeletal muscle-type EC coupling
without reducing LTCC density
The data presented thus far show that with respect to its cur-
rent properties and pharmacological modulation CaV1.1e
behaves similar to other L-type calcium channels. However,
with respect to EC coupling it exhibits the distinctive
skeletal muscle specific attributes: CaV1.1e can activate
sarcoplasmic reticulum (SR) calcium release without cal-
cium influx either at depolarizations to the reversal poten-
tial, or in the presence of the nonspecific calcium channel
blocker Cd2+/La3+ (4). In the classical/adult CaV1.1a splice
variant the molecular interactions underlying the skeletal
muscle-specific EC coupling mechanism is also important
for the expression of normal, albeit small, calcium currents.
CaV1.1a constructs with sequence substitutions in the
cytoplasmic II-III loop that prevented EC coupling (i.e.,
orthograde coupling of the CaV1.1a voltage sensor to the
RyR1 calcium release channel) also prevented the RyR1-
dependent augmentation of LTCC (i.e., retrograde coupling)
(6–8).
To study whether the expression of the large calcium
currents of CaV1.1e in skeletal muscle cells also requires
direct interactions with the RyR1, we generated a CaV1.1e
in which the II-III loop has been replaced by the corre-
sponding but highly heterologous sequence of the Musca
channel (CaV1.1e-SkLM; Fig. 3 A). When expressed in
dysgenic myotubes CaV1.1e-SkLM was normally incor-
porated into peripheral junctions and developing triads,
as indicated by its colocalization with RyR1 clusters at
the cell surface (Fig. 3 B). Thus, CaV1.1e-SkLM fulfills
the basic structural condition for a functional interaction
with the RyR1.Biophysical Journal 108(5) 1072–1080Next, dysgenic myotubes expressing either the wild-type
CaV1.1e or CaV1.1e-SkLM were analyzed in parallel with
combined whole-cell patch-clamp measurements and fluo-
rometric recordings of the fluorescent calcium indicator
fluo-4. Fig. 3 C shows representative traces of the cyto-
plasmic calcium transients (top) and calcium currents
(bottom) at depolarizing steps to the maximally activating
voltages. Plotting the voltage-dependence of peak calcium
transients and calcium currents (Fig. 3 D) shows that
calcium transients and calcium currents of CaV1.1e and
CaV1.1e-SkLM activate in parallel at the same voltages.
Whereas at the reversal potential of þ80 mV current
densities decline to near zero, CaV1.1e calcium transients
are still substantially activated, consistent with calcium
influx-independent activation of SR calcium release (i.e.,
skeletal muscle EC coupling). Calcium currents in myo-
tubes expressing the chimeric CaV1.1e-SkLM channel
are very similar in size and voltage-dependence to those
of CaV1.1e. However CaV1.1e-SkLM calcium transients
are greatly reduced in amplitude compared to those of
CaV1.1e and they strongly decline at higher voltages, sug-
gesting a strong dependence on the calcium influx. Appli-
cation of 0.5 mM Cd2þ/0.2 mM La3þ efficiently blocks
the calcium currents at all voltages. In parallel calcium tran-
sients are abolished, indicating that the remnant calcium
transients observed with CaV1.1e-SkLM are fully dependent
on calcium currents. Thus, the small CaV1.1e-SkLM
calcium transients arise from calcium influx through the
CaV1.1 channel and possibly from calcium-induced calcium
release from the SR (i.e., cardiac-type EC coupling (19)).
Evidently, the sequence substitution in the II-III loop of
the CaV1.1e-SkLM channel has totally abolished skeletal
muscle-type EC coupling. This corresponds to what has
previously been shown for CaV1.1a-SkLM (6) and indicates
that in CaV1.1e-SkLM the direct coupling between the
CaV1.1 voltage sensor and the RyR1 has been severed.
Nevertheless, the amplitude of its calcium currents was
unchanged, demonstrating that CaV1.1e-SkLM’s current
size does not depend on II-III loop interactions with the
RyR1. Thus, CaV1.1e is not modulated by retrograde
coupling.DISCUSSION
The skeletal muscle CaV1.1 is unique among the voltage-
gated calcium channels in that it can activate SR calcium
release independent of calcium influx by direct interactions
with the RyR1. In the adult channel variant CaV1.1a this
comes at the price of poor current properties. However,
the embryonic CaV1.1e splice variant combines both skel-
etal muscle-type EC coupling properties with perfectly
fine current properties. Here, we asked the questions
of whether and how CaV1.1e calcium currents can be
modulated; physiologically by retrograde interactions
with the RyR1 and pharmacologically by DHPs. Our data
FIGURE 3 CaV1.1e calcium currents are not augmented by retrograde coupling with the RyR1. (A) Domain structure of CaV1.1 depicting the location of
the sequence coded by exon 29 (red), which is missing in the embryonic CaV1.1e variant, and the II-III loop that has been swapped with the nonfunctional
loop of the Musca channel in CaV1.1e-SkLM (green). (B) Double-immunofluorescence labeling of CaV1.1e variants and the RyR1 in dysgenic myotubes
transfected with either CaV1.1e or CaV1.1e-SkLM. Both channels form clusters colocalized with the RyR1. Bar, 10 mm. (C) Representative current traces
and fluorescence calcium recordings from myotubes expressing CaV1.1e or CaV1.1e-SkLM. (D) Voltage-dependence of peak current densities and fluores-
cent calcium transients. CaV1.1e-SkLM (green), compared to CaV1.1e (red), expresses similar size calcium currents but decreased calcium transients, which
are fully blocked by Cd2þ/La3þ (gray). To see this figure in color, go online.
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29 in CaV1.1e precludes further enhancement of the current
by retrograde coupling, 2) the CaV1.1e currents can be
further augmented by L-type current agonist Bay K 8644,
and 3) blocked by L-type current antagonist nifedipine.
These findings have important implications for understand-
ing the molecular mechanisms regulating current activation
and EC coupling in the skeletal muscle calcium channels,
for understanding the function of the embryonic CaV1.1e
splice variant in EC coupling, and for assessing its potential
as drug target in myotonic dystrophy.CaV1.1e is not subject to retrograde coupling
When the crucial sequences for CaV1.1-RyR1 interaction in
CaV1.1e were eliminated, EC coupling failed but surpris-
ingly the calcium currents were not affected. This finding
is unexpected because CaV1.1a and CaV1.1e, which differonly with respect to the inclusion of 19 amino acids in an
extracellular loop of CaV1.1a, interact with the RyR1 in
the same way, and because earlier experiments with the
adult splice variant CaV1.1a demonstrated that retrograde
coupling is linked to orthograde coupling (skeletal mus-
cle-type EC coupling) by their dependence on the same
critical sequences in the II-III loop (6–8). Based on these
studies orthograde and retrograde coupling were viewed as
the two sides of the same coin. The same mechanism
enabling depolarization-induced activation of the RyR1 in
one direction was thought to facilitate CaV1.1a channel
gating in the reverse direction. In light of our present find-
ings this model needs to be amended (Fig. 4), because in
CaV1.1e the skeletal muscle EC coupling mechanism is
fully functional, but this does not facilitate gating of the
CaV1.1e channel. Apparently, retrograde coupling is only
effective in a situation in which the calcium current is cur-
tailed in the first place. Thus, in CaV1.1a, where aBiophysical Journal 108(5) 1072–1080
FIGURE 4 Gating model explaining the effects of exon 29 and the II-III
loop-RyR1 interactions on skeletal muscle calcium currents. (A) In the adult
splice variant CaV1.1a the presence of the extracellular loop encoded by
exon 29 impedes channel gating (red domain IV). However, interactions
of the II-III loop with RyR1 counteract and partially alleviate this inhibition
(green), enabling small calcium currents in wild-type CaV1.1a. Without this
interaction, as in the CaV1.1a-SkLM mutant, exon 29-containing channels
conduct virtually no currents. In the absence of exon 29 in the embryonic
splice variant CaV1.1e there is no current inhibition by domain IV. Con-
sequently, there is nothing to alleviate by the II-III loop interactions with
RyR1 and its substitution in CaV1.1e-SkLM does not alter the current
density. (B) Our current and published data are best explained by a model
according to which retrograde coupling with the RyR1 relieves an inhibi-
tory mechanism that exists in CaV1.1a but not in CaV1.1e. Without coupling
to the RyR1 the intrinsic inhibitory mechanism affected by exon 29 prevails
in CaV1.1a-SkLM. In the absence of this inhibitory mechanism, as in
CaV1.1e and CaV1.1e-SkLM, retrograde coupling is ineffective. To see
this figure in color, go online.
1078 Benedetti et al.mechanism depending on exon 29 curtails the calcium cur-
rents, the retrograde coupling mechanism may partially alle-
viate this limiting effect. In CaV1.1e, however, where this
limiting mechanism does not exist, retrograde coupling is
no longer functional or necessary.
In this context it is important to note that the alleviating
effect of retrograde coupling on the poor channel pro-
perties of CaV1.1a is specific and incomplete. Specific,
because it only augments the current amplitude but does
not rescue the poor voltage sensitivity of CaV1.1a. This
is consistent with a recent report showing that dialysis
of a 36 amino-acid peptide from the central domain
of RyR1 into skeletal muscle fibers augmented CaV1.1
current amplitude but not its voltage-dependence (20).
Furthermore, the alleviation of current inhibition in
CaV1.1a is incomplete, because despite retrograde coupling
CaV1.1a current amplitudes are still severalfold lower than
those of CaV1.1e.
Nevertheless, augmentation of currents by retrograde
coupling is somehow linked to the mechanism that limits
current amplitude and voltage sensitivity of CaV1.1a.
From a structural point of view it is intriguing to consider
how in CaV1.1a the interaction of the RyR1 with the cyto-
plasmic loop between homologous domains II and III of
the channel can counteract a mechanism that is dependent
on the presence of an extracellular loop in domain IVBiophysical Journal 108(5) 1072–1080encoded by exon 29. However, a recent study of CaV1.2
voltage sensor movements demonstrated a strong allosteric
coupling of the four repeats (21), suggesting that alternative
splicing or altered protein-protein interactions in any one of
the four voltage sensor domains might affect movement of
the others as well. Along this line it is conceivable that
exclusion of exon 29 might affect gating properties by
altering interactions with auxiliary channel subunits. How-
ever, previously we have shown that CaV1.1e was still sen-
sitive to shRNA knockdown of a2d-1 (4), and functional EC
coupling implies intact interaction of CaV1.1e with b1a (22).
Whether CaV1.1e also interacts with the g1 subunit, which
has been shown to modify EC coupling as well as DHP
binding (23), is still elusive.CaV1.1e-SkLM reveals the contribution of
calcium-induced calcium release in CaV1.1e
expressing muscle cells
Previously, we demonstrated that voltage-activated calcium
transients in CaV1.1e expressing myotubes are composed of
a major current-independent component and a minor cur-
rent-dependent component, which could be selectively
blocked by Cd2þ/La3þ (4). Thus, EC coupling in embryonic
muscles, which predominantly express the CaV1.1e variant,
combines skeletal muscle and cardiac muscle EC coupling
mechanisms. Here, we replaced the II-III loop of the
CaV1.1e splice variant with the corresponding loop of the
Musca channel to specifically eliminate the skeletal mus-
cle-type EC coupling component. Whereas the identical
sequence substitution in CaV1.1a fully disrupted skeletal
muscle EC coupling (7), myotubes expressing CaV1.1e-
SkLM still displayed sizable calcium transients. The finding
that these calcium transients were fully abolished when cal-
cium currents were blocked with Cd2þ/La3þ, confirms that
also in the context of CaV1.1e the II-III loop substitution
completely blocked skeletal muscle-type EC coupling.
Furthermore, it demonstrated that the small calcium
transients in myotubes expressing CaV1.1e-SkLM were
completely dependent on calcium influx through the
mutated CaV1.1e channel. Most likely the transients
combine the calcium entering the myotubes through
CaV1.1e-SkLM plus calcium released from the SR by
calcium-induced calcium release by RyR1. In agreement
with previous studies (19), this shows that skeletal muscles
are capable of cardiac muscle-type EC coupling if the
channels conduct calcium. At depolarizations to þ30 mV
the fraction of this influx-dependent EC coupling compo-
nent accounts for approximately one-quarter of the total
CaV1.1e calcium transients, whereas three quarters repre-
sent the current-independent direct EC coupling component.
Therefore, in muscle cells expressing the embryonic
CaV1.1e splice variant, the calcium current-dependent
component represents a substantial fraction of the total
calcium signal in EC coupling.
Pharmacology and Modulation of CaV1.1e 1079CaV1.1e is sensitive to activation or block by DHPs
Given the fact that all CaV1 channels studied so far are sen-
sitive to DHPs and because the known binding site for DHPs
(24) is not directly affected by skipping of exon 29, it was to
be expected that also CaV1.1e would be DHP sensitive.
Nevertheless, the DHP sensitivity of the CaV1.1e splice
variant remained to be demonstrated. On the other hand,
the II-III loop sequences also known to be responsible for
retrograde coupling were not touched by skipping of exon
29, and still CaV1.1e currents failed to be modulated by
retrograde coupling. Moreover, the mode of current modula-
tion by the DHP agonist Bay K 8644 (11) closely resembled
the effects of exon 29 skipping, suggesting the possibility
that both the channel agonist and the current-enhancing ef-
fect of deleting exon 29 might act on the same downstream
gating mechanism. However, our pharmacological charac-
terization of CaV1.1e clearly demonstrated that the effects
of Bay K 8644 and lack of exon 29 were additive, indicating
that the deletion of exon 29 did not abolish the molecular
mechanism of drug action. However, the magnitude of the
Bay K 8644 effect was substantially lower compared to
CaV1.1a. This could either reflect a reduced Bay K 8644
sensitivity of the CaV1.1e splice variant or result from a
saturation of the maximal conductance. Because CaV1.1e
channels already have a ~10-fold higher open probability
(4) the remaining dynamic range for pharmacological cur-
rent enhancement may be limited compared to CaV1.1a.
We further show that CaV1.1e is also sensitive to the
L-type channel antagonist nifedipine. This is important for
the potential use of L-type channel blockers in the therapy
of myotonic dystrophy. Tang et al. (9) demonstrated that
in myotonic dystrophy type 1 and type 2 the splicing of
CaV1.1 was misregulated and that in muscles of adult
human patients the degree of CaV1.1e expression correlated
with the severity of muscle weakness. Furthermore, forced
skipping of exon 29 increased the number of central nuclei
in muscles of a mouse model for myotonic dystrophy.
Recently, it has been shown that expression of calcium regu-
lating proteins and cytoplasmic calcium handling are dysre-
gulated in cultured myotubes from myotonic dystrophy
patients (10). Together, these findings strongly implicate
altered calcium signaling and in particular overexpression
of the embryonic splice variant CaV1.1e in mature muscles
in the pathophysiology of myotonic dystrophy. Thus, the use
of clinically approved calcium channel blockers may be
beneficial for patients suffering from myotonic dystrophy.
Since in adults expression of CaV1.1e is strongly increased
in muscles affected by myotonic dystrophy the expected
therapeutic effect would be specific for diseased muscle
and because CaV1.1e expression levels correlate with mus-
cle weakness the effect would be greater the worse the dis-
ease. Whereas side effects on the virtually nonconducting
adult skeletal muscle CaV1.1a splice variant would not be
an issue, a confounding factor will be the known effectsof these drugs on cardiovascular function. Our finding that
the IC50 of nifedipine action on CaV1.1e (0.37 mM) is in
the same range as that reported for the CaV1.2, the major
target for DHPs in smooth muscle cells, indicates that at
the therapeutic dose side effects like hypotension would
be expected.CONCLUSIONS
In conclusion, our biophysical analysis of the embryonic
splice variant CaV1.1e indicates that CaV1.1e LTCC are
not subject to retrograde coupling with the RyR1 and that
the physiological current modulation of CaV1.1a by retro-
grade coupling converges on the same molecular mecha-
nism by which inclusion of the sequences encoded by
exon 29 limits the size of the calcium current. On the other
hand, our pharmacological characterization of CaV1.1e
demonstrates that the channel agonist Bay K 8644 and
inclusion of exon 29 use distinct molecular mechanisms
for current enhancement. Its sensitivity to DHP calcium
channel blockers identifies CaV1.1e as a potential drug
target for the treatment of myotonic dystrophy.ACKNOWLEDGMENTS
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